Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) — Tangible Net Worth Ratio
Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) has a Tangible Net Worth Ratio of 91.8% as of March 2026. This metric is calculated by deducting intangible assets (CN¥980.99 Million) from net assets (CN¥11.99 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore 603392 net asset momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Tangible Net Worth Ratio (2013–2025)
This chart shows how Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Tangible Net Worth Ratio has changed across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 91.8%, reflecting net assets of CN¥11.99 Billion with intangible assets of CN¥980.99 Million CNY. For live market cap and overall valuation, see market value of Beijing Wantai Biological Pharmacy Enter.
Annual Tangible Net Worth Ratio for Beijing Wantai Biological Pharmacy Enterprise Co Ltd (2013–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Beijing Wantai Biological Pharmacy Enterprise Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore how much does Beijing Wantai Biological Pharmacy Enter reinvest in capital to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 92.0% | CN¥12.03 Billion | CN¥962.96 Million | CN¥14.04 Billion | ▼ -2.3 pp |
| 2024 | 94.3% | CN¥12.45 Billion | CN¥712.86 Million | CN¥14.69 Billion | ▼ -0.7 pp |
| 2023 | 95.0% | CN¥12.88 Billion | CN¥642.74 Million | CN¥15.71 Billion | ▼ -2.3 pp |
| 2022 | 97.4% | CN¥12.56 Billion | CN¥332.38 Million | CN¥16.23 Billion | ▲ +3.8 pp |
| 2021 | 93.5% | CN¥4.56 Billion | CN¥295.13 Million | CN¥7.05 Billion | ▲ +2.6 pp |
| 2020 | 90.9% | CN¥2.58 Billion | CN¥233.95 Million | CN¥3.50 Billion | ▲ +6.2 pp |
| 2019 | 84.7% | CN¥1.58 Billion | CN¥242.03 Million | CN¥2.16 Billion | ▲ +2.8 pp |
| 2018 | 81.8% | CN¥1.37 Billion | CN¥248.87 Million | CN¥1.81 Billion | ▲ +10.1 pp |
| 2017 | 71.8% | CN¥898.99 Million | CN¥253.90 Million | CN¥1.66 Billion | ▼ -0.8 pp |
| 2016 | 72.6% | CN¥959.70 Million | CN¥263.05 Million | CN¥1.45 Billion | ▼ -0.6 pp |
| 2015 | 73.2% | CN¥722.69 Million | CN¥193.40 Million | CN¥1.10 Billion | ▼ -17.3 pp |
| 2014 | 90.5% | CN¥580.32 Million | CN¥55.08 Million | CN¥805.50 Million | ▲ +5.2 pp |
| 2013 | 85.3% | CN¥382.06 Million | CN¥56.31 Million | CN¥606.98 Million | — |